Clinical Trials
5 trialsNCT05400122 2025-11-12
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Phase 1 Suspended
NCT03724851 2025-03-25
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
MedPacto, Inc.
Phase 1/2 Completed
NCT03698825 2024-12-09
TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer
MedPacto, Inc.
Phase 1/2 Completed
NCT04893252 2022-11-30
Vactosertib and Durvalumab in Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT04656002 2022-06-15
As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers
Samsung Medical Center
Phase 2 Unknown